Verify regulatory 503A compliance and calculate out-of-pocket savings for compounded Tirzepatide & Semaglutide in District of Columbia compared to retail commercial list prices ($1250/mo).
Status: DC Municipal Regs Title 17-65
District of Columbia permits licensed telehealth medical providers to prescribe verified compounded GLP-1 medications through certified 503A pharmacies.
Statutory Citation: DC Board of Pharmacy Compounding Standards
District of Columbia permits licensed telehealth medical providers to prescribe verified compounded GLP-1 medications through certified 503A pharmacies.
Yes, under FDA 503A statutory guidance and District of Columbia Board of Pharmacy rules, certified compounding pharmacies may dispense patient-specific formulations.
Average cash-pay clinical telehealth subscriptions in District of Columbia average $295/month, compared to $1,250/month for retail commercial brands.
Yes. District of Columbia permits synchronous telehealth physician evaluations and direct refrigerated shipping from licensed 503A facilities.
Explore statutory rules, state benchmarks, and customized calculation models across all 51 jurisdictions.
Browse deep clinical analysis and metabolic decision models on Groundwork.